BioArctic (BIOA-B.ST)

Executive Summary

BioArctic AB is a Swedish biopharmaceutical company focused on neurodegenerative diseases, with its lead asset lecanemab (Leqembi®) approved for Alzheimer's disease through a partnership with Eisai. The company leverages its proprietary BrainTransporter® platform and protein aggregate targeting technology. BioArctic's pipeline includes exidavnemab, an anti-alpha-synuclein antibody in Phase 2 for Parkinson's disease (PD) and multiple system atrophy (MSA). The company's market valuation of ~$28 billion reflects the commercial success of lecanemab and potential of its early-stage pipeline. Upcoming catalysts include Phase 2 data readouts for exidavnemab, which could validate its platform for synucleinopathies. With a strong balance sheet and established partnership, BioArctic is well-positioned for long-term growth.

Upcoming Catalysts (preview)

• Q3 2026Exidavnemab Phase 2 Top-Line Data in Parkinson's Disease55% success